Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Pristimerin exacerbates injury in conditionally reprogrammed patient-derived lung cancer cells

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Presentation
  • By: TANG, Yubo (Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, China)
  • Co-author(s): Yubo Tang: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Chao Cheng: Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Xuenong Zou: Department of Orthopaedic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Xiao Chen: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
  • Abstract:

    Background

    Lung cancer is the most common and lethal malignant disease for which the development of efficacious chemotherapeutic agents remains an urgent need. Pristimerin (PRIS), a natural component known from Celastraceae families, exerts anti-tumor effect in several types of cancer. However, the underlying mechanisms involved remains unclear.

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses